| Bioactivity | Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2]. |
| Name | Tagitanlimab |
| CAS | 2417649-97-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24(Suppl 1):S21-S30. [2]. Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410. |